Saturday, 6 September 2008
Gender Bias Seen In Response To Common Antidepressant
The persistence of a grammatical gender difference in response to the dose - even after the researchers accounted for many complicating factors - suggests that there's a genuine biological difference in the way the medication affects women compared with manpower. The reasons for that difference are still ill-defined, but further studies ar now examining hormonal variations that may play a role.
The survey involved citalopram, a commonly used antidepressant that is available both as a generic drug and under the brand name name Celexa.
Researchers from the University of Michigan Depression Center and their colleagues from around the country tested the drug's ability to help depression patients achieve remission, or tot up relief from their symptoms, in a multi-year study called STAR*D.
The gender differences emerged from a detailed analysis of data from 2,876 men and women wHO had a clear diagnosing of major depression, and took citalopram over a number of weeks, with the doses increasing over time.
In the end, women were 33 percent more likely to achieve a full remitment of their depression, contempt the fact that women in the study were more hard depressed than the workforce when the study began.
The study showed no differences between work force and women in side effects, the amount of time that patients stuck to pickings the do drugs, or the amount of time it took for them to achieve remitment of their symptoms.
The new findings, which represent the largest and most stringent analysis ever of grammatical gender differences in response to an antidepressant drug, are published online in the Journal of Psychiatric Research.
Elizabeth Young, M.D., a professor and associate chair of psychological medicine at the U-M Medical School and member of the Depression Center, is the study's lead source. "Other studies have suggested that thither are differences between work force and women in response to different antidepressants, merely the grounds has been conflicting," she says. "This study is large enough, and we were able to control for enough complicating factors, that we feel surefooted there is a true difference. These results have clear implications for the clinical treatment of depression."
Young and her colleagues, including Susan Kornstein, M.D., of Virginia Commonwealth University, and John Rush, M.D., at one time of the University of Texas Southwestern Medical Center at Dallas, conducted the analysis of data from men and women 'tween the ages of 18 and 75, many of whom were being treated by primary care physicians and non psychiatrists. All of the patients had been experiencing depression for years, with the mean length of experience around 12 years.
The study was funded by the National Institute of Mental Health. Unlike many previous industry-sponsored studies of antidepressants, it included a "real world" sample of people with major depression, and did not shut out people world Health Organization had a history of suicidal thought process. The study did non include people with bipolar disorder. Participants in the study could continue with psychotherapy that they had been undergoing before the start of the study, but could take no other antidepressants.
Citalopram is ane of a class of medicines known as SSRIs, or selective serotonin re-uptake inhibitors. In earlier decades, gender differences had been seen in studies of patients pickings an older generation of drugs called tricyclics, with men aid to answer better to such medications. But for more than 15 age, SSRIs feature been the first selection for treating depression.
Although the current study didn't look at hormonal variations between men and women that might account for the difference in response to citalopram, Young and her colleagues note that brute studies have shown that estrogen modifies the brain systems involved in the activity of serotonin, a key nous chemical.
Kornstein is leading further analysis of the STAR*D results to look for possible differences among women according to their menopausal status and their utilisation of hormone replacement therapy. Meanwhile, Young's research as a fellow member of the U-M Molecular & Behavioral Neuroscience Institute focuses on the interactions of sex hormones and stress reaction in depression and other mood disorders.
Overall, women are more unnatural by impression than work force, with about 12 percent of women suffering from some form of depression in a given class compared with 6 per centum of workforce. Depression and other mood disorders are the leading cause of disability among women under the eld of 45.
But the study's authors are quick to caution that their findings don't hateful that citalopram should merely be used in women. Raw data from the study render that 24 percent of men achieved remission with the do drugs, compared with 29 percent of women. The remainder in remission rates grew larger in one case the researchers adjusted for other factors, but the fact remains that many men were helped.
Rather, they note that STAR*D and other studies have shown that many people with depression motive to stress several treatments to find the nonpareil that's right for them and will produce lasting results.
That's wherefore a fresh study called CO-MED has begun. Young and colleagues from U-M and around the country are at present enrolling people with clinical depression for this study that will assess the shock of combinations of medications. One of the medications in that study is escitalopram, a cousin of citalopram, merely it likewise includes former common SSRI antidepressants.
More information on the CO-MED study is available at hTTP://www.depressioncenter.org/research/co-med.naja haje. Information on STAR*D is available at http://www.nimh.nih.gov/health/trials/practical/stard.
In addition to Young, Kornstein and Rush, the study's authors include Sheila Marcus of the U-M Depression Center, Madhukar Trivedi and Diane Warden of UT-Southwestern, Anne Harvey of Via Christi Research, Stephen Wisniewski and G.K. Balasubramani of the University of Pittsburgh and Maurizio Fava of Harvard Medical School.
Reference: Journal of Psychiatric Research, doi:10.1016/j.jpsychires.2008.07.002
Source: Kara Gavin
httUniversity of Michigan Health System
View do drugs information on Celexa.
More info
Wednesday, 27 August 2008
Ambulance Trust Has Made Improvements Since Tragic Death, Finds Healthcare Watchdog
The Commission's intervention follows concerns about an incident in May 2007, which ended in the death of a woman wHO was involved in a road dealings accident. The ambulance took 42 proceedings to assist the scene at Cirencester in Gloucestershire - 34 minutes over the interior target of eight proceedings for attending an fortuity of this kind.
The Commission had also been aware of concerns that the % Commission
More info
Sunday, 17 August 2008
Mp3 music: T-Rio
Artist: T-Rio: mp3 download Genre(s): Other T-Rio's discography: (Choopeta) Mamae Eu Quero Year: 2004 Tracks: 3 T-Rio consist of triplets ThaÃsa, Thainá, and Thayan, world Health Organization ar dancers and actors as well as musicians. Born on November 10, 1984, in Brasilia, the siblings began dance at a very danton True Young years, immersing themselves in the worlds of authoritative ballet, jazz, and contemporary dance, as good as dabbling in playacting. The public took to them immediately, and the sisters shortly base themselves in Spain acting with the popular group Sandy & Júnior. After relocating to Rio de Janeiro, the girls began composing their own material. A theatre job in France provided opportunities for the leash to arm out on their possess, and in 2004 they released their first |
Download Carly Simon
Thursday, 7 August 2008
Andreas Kremer and Friends
Artist: Andreas Kremer and Friends
Genre(s):
Techno
Discography:
Do U Love Techno Vinyl
Year: 2003
Tracks: 1
 
Tuesday, 1 July 2008
Jen and John - Who's Really Gettin' It
Wednesday, 25 June 2008
Flaw
Artist: Flaw
Genre(s):
Rock
Other
Metal: Alternative
Discography:
Recognize
Year: 2004
Tracks: 1
Endangered Species
Year: 2004
Tracks: 12
Through The Eyes
Year: 2001
Tracks: 13
Flaw
Year: 1998
Tracks: 11
A fivesome from Louisville, KY, Flaw aims at creating relevance and lively signification to the nu metallic element scene, victimization it as the foundation for dynamical, hard-driven music. The core of Flaw pulled together in 1996 when Jason Daunt placed an ad for a guitarist and Chris Volz answered. Volz's adopted mother, an opera singer world Health Organization had performed at the Kennedy Center, had helped get his musical talent. After she attached self-annihilation when Volz was 12, he fagged old age in assorted types of psychotherapy, gaining insights that electrical shunt nigh people. It was from this have that Volz shaped his personal style of lyrics, expressing how one gets through inner turmoil and hurts. Songs such as "Internal Strength," "Whole" (a song about his mother's death), and "Only if the Strong" reflect his internal growth.
To begin with calling themselves F. Law, the group distinct it was more undetermined than the nominate implied, that everyone and everything has flaws. Thus, they dropped the period and became Flaw. In 1997, Ryan Jurhs (five-string bass, screen background vocals) joined with Volz and Daunt, spell the rest of the lineup unbroken revolving. Jurhs had just finished his erolia minutilla with the Marines and was connexion the music picture. Within a few weeks, Flaw recorded their first indie record, American Arrogance. Two of the vIII tracks, "Amendment" and "Reliance," are also on the band's official debut record album, Through the Eyes. The indie record opened the door for Flaw to open for bands such as Econoline Crush and Fear Factory. The band place prohibited iI more independent records, Flaw in 1998 and Drama EP in 2000, both of which were well-received. Flaw's lineup firmed up in 1999 when Chris Ballinger (drums) and Lance Arny (guitar) came aboard. Arny tended toward organism a technical player, spell Daunt went for the impromptu odd sounds, and Volz aimed his lyrics at the healing litigate in life and childhood. The combination worked.
In 2000, Flaw showcased at CBGB in New York where Republic/Universal heard them and signed them up. With David Bottrill (world Health Organization had interpreted Tool and Peter Gabriel to the round top) as their manufacturer, Flaw began recording at Sound City in Los Angeles in early 2001. Republic/Universal released Flaw's official debut album, Through the Eyes, in October 2001 in both clean and explicit versions. While the album had a tinge of the Tool influence, the singularity of Flaw remained solid and the album standard rave reviews.
F.S. Blumm
Wednesday, 11 June 2008
Kiss - Kiss Reality Show To Replace Simmons And Stanley
KISS rockers GENE SIMMONS and PAUL STANLEY are planning a reality show to hire their own replacements when they quit the band.
During an interview with a reporter in Norway, Simmons revealed a deal has already been done and that the show would begin shooting this year (08).
He told Roy Hilmar Svendson, "We have already signed the contract, and it is going to go through in a couple of months."
Paul Stanley has poured scorn on Simmons claims - but confirms they are discussing the idea. He is quoted on Blabbermouth.net saying, "These things are typical. Gene says something as if it was a fact, but there is no signed deal. The future has many possibilities. Will it happen next week? No! Am I opposed to the idea? Of course not."
Neither of the pair has revealed when they plan to leave the band, but earlier this year, Stanley admitted he was coming close to retiring: He said, "I really, firmly believe there will come a time when the band will continue without me."
See Also

